Forest Labs
Executive Summary
Sales of influenza A treatment Flumadine were $11 mil. in the fiscal third quarter ended Dec. 31. Forest attributed the "highly successful launch" to the predominance of type A influenza in a strong flu season. "There was, of course, heavy promotional expense associated with the Flumadine launch," Forest said